Platelets are critical in haemostasis, coagulation and thrombosis. Recently, the influence of the platelet has been found to extend far beyond haemostasis to inflammation, wound healing and vascular remodelling. The molecular basis of the role of the platelet in inflammation is poorly understood. Thus it was of considerable interest when in 1998, Henn et al demonstrated that platelets express membrane-bound CD40L upon activation 1 . CD40L is a membrane protein belonging to the tumour necrosis factor family and of critical importance in the adaptive immune response in innate immunity and in inflammation. Henn et al demonstrated that platelet CD40L has the capacity to bind to endothelial cell CD40 and induces these cells to express adhesion molecules and tissue factor, and to produce pro-inflammatory cytokines. Since then, it has been shown that platelet CD40L can induce monocytes to express tissue factor through monocyte CD40 2 .
Recent studies with CD40L -/mice have also demonstrated a role for CD40L in platelet adhesion. CD40L has a KGD integrin-binding sequence at position 115-118, enabling it to bind directly to αIIbß3, the major platelet adhesion molecule, and to promote platelet adhesion under shear 3 .
Platelet CD40L is thus likely to be a pivotal link between the processes of thrombosis and inflammation. As such, platelet CD40L is likely to be of particular importance in inflammatory conditions involving the vascular endothelium such as sepsis syndrome, meningococcal disease, sickle cell anaemia, vasculitis and atherosclerosis.
In support of this, in mouse models of several chronic inflammatory conditions, inflammation can be reduced by disrupting the CD40-CD40L system.
Additionally, platelet or sCD40L is elevated in the plasma of humans with an array of inflammatory conditions, such as chronic renal failure, sickle cell anaemia, systemic lupus erythematosus, acute coronary syndromes and Kawasaki disease.
We have therefore investigated the role of platelet CD40L in inflammatory cell interactions in the laboratory and in the inflammatory process in childhood sepsis and sickle cell anaemia.
Firstly, the presence of CD40L on platelets was confirmed using flow cytometry and immunohistochemistry and the subcellular location demonstrated to be the α-granule membrane using immunoelectron microscopy. A rapid technique was developed to determine expression of CD40L on activated platelets by flow cytometry in whole blood 4 . This technique was used in all the other work described here.
Secondly, the capacity of platelet CD40L to induce monocyte cytokine production was investigated using a whole blood flow cytometric assay of intracellular cytokine production. This work demonstrated that blood monocytes, in spite of constitutively expressing CD40, do not respond to platelet derived CD40L. Further investigation was performed using THP-1 cells (a monocytoid cell line) and demonstrated that THP-1 cells did not respond to sCD40L or platelet CD40L under resting conditions. However, following co-culture with interferon-γ, which up-regulated surface CD40 in THP-1 cells, sCD40L (but not platelet CD40L) induced production of IL-8 and TNF-α. Taken together, these findings are important as they may indicate a limited role for platelet CD40L in the induction of monocyte cytokine production.
Thirdly, the role of CD40L in platelet-platelet cross talk was investigated. Platelets were found to constitutively express CD40 and to become activated following ligation of CD40 with sCD40L. Ligation of platelet CD40 caused increased platelet CD62P expression, alpha-granule and dense granule release, and the classical morphological changes associated with platelet activation. CD40 ligation also caused ß3 integrin activation, although this was not accompanied by platelet aggregation. These actions were abrogated by the CD40L blocking antibody TRAP-1 and the CD40 blocking antibodies M2 and M3, showing that activation was mediated by CD40L binding to platelet CD40. ß3
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The role of platelet CD40L in inflammation ICS Research Gold Medal Abstract Presenters continued 29 integrin blockade with eptifibatide had no effect, indicating that outside-in signalling via aIIbß3 was not contributing to these CD40-mediated effects. CD40 ligation led to enhanced platelet-leukocyte adhesion, which is important in the recruitment of leukocytes to sites of thrombosis or inflammation. These results support a role for CD40-mediated platelet activation in thrombosis, inflammation, and atherosclerosis 5 .
These findings prompted an investigation of the role of platelet CD40L in children with meningococcal sepsis (MS) and sickle cell anaemia 6 . The MS study looked at three aspects of platelet CD40L. Firstly, ELISA was performed of plasma from patients with MS (n=48) and age-matched controls (n=10) for sCD40L levels. Secondly, flow cytometry was performed on fresh blood from patients with MS (n=10) and age matched controls (n=10) for membrane bound CD40L on circulating platelets. Thirdly, immunohistochemistry was performed on skin biopsy specimens from patients with MS, staining for platelet CD40L expression in microthrombi. sCD40L levels were found to be higher in patients (0.29 ng/ml, 0.2-0.4; median, IQR) than controls (0.09 ng/ml, 0.09-0.12), p<0.0001 (Mann Whitney U test). Circulating platelets expressed low levels of CD40L in both patients (3.5% CD40L+ platelets, 3.0, 4.8) and controls (4.9% CD40L+ platelets, 3.5-5.8), p=0.21 (Mann Whitney U test). Immunohistochemistry demonstrated platelet CD40L in microthrombi in skin lesions in close apposition to the vascular endothelium. The higher sCD40L level in acute MS probably reflects release of sCD40L from circulating platelets. The absence of activated CD40L+ platelets in the circulation and their presence in microthrombi in skin lesions is consistent with recruitment to sites of endothelial injury. Thus, platelet CD40L may be an important pro-inflammatory and pro-thrombotic stimulus in MS 7 .
This work is an important addition to the current understanding of platelet CD40L. However, further work must be done to refine the understanding of the role of platelet CD40L in inflammation both in vitro and in vivo before clinical studies looking at blocking the effect of platelet CD40L can be performed. As CD40L binds to the ligand binding site of activated αIIbß 3 , it may also be possible to block this interaction with αIIbß3 blocking agents 8 . The CD40L-CD40 interaction could be blocked with either CD40 or CD40L blocking antibodies. Once the role of platelet CD40L in inflammation is more fully understood, future clinical studies are likely to focus on investigating such strategies in conditions as diverse as acute coronary events, stroke, vasculitis and sepsis syndrome.
